Back to News
Market Impact: 0.2
Orion Pharma, Qilu Partner On Pembrolizumab Biosimilar In Europe
Source: Nasdaq
Healthcare & BiotechProduct Launches
Orion Corp. and Qilu Pharma Europe agreed to commercialise an intravenous pembrolizumab biosimilar in Europe. The announcement provides no financial terms, launch timing, or expected sales figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ORNBV0.55
More News
- Meta may ditch the idea of a cloud business for Muse. We think that’s a good trade
- Why is Telix Pharmaceuticals stock rallying today?
- Mistral unveils new AI model it says rivals best open systems from China
- Muse has been a boon for Meta. It can soar much higher, Wells Fargo says
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)